Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
D000726:Androgen Antagonists / Q000627:therapeutic use*; D000813:Anilides / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D005485:Flutamide / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D048289:Imidazolidines; D008297:Male; D009570:Nitriles; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D014105:Tosyl Compounds
D000726:Androgen Antagonists; D000813:Anilides; D007093:Imidazoles; D048289:Imidazolidines; D009570:Nitriles; D014105:Tosyl Compounds; D017373:Cyproterone Acetate; C021277:nilutamide; D005485:Flutamide; C053541:bicalutamide